Amgen (NASDAQ:AMGN) Updates FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 22.300-23.500 for the period, compared to the consensus estimate of 22.390. The company issued revenue guidance of $38.2 billion-$39.4 billion, compared to the consensus revenue estimate of $37.8 billion.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. Wells Fargo & Company boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Robert W. Baird raised their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday. Mizuho upped their price objective on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Guggenheim lifted their target price on shares of Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $363.70.

Amgen Stock Up 5.0%

Shares of NASDAQ:AMGN traded up $19.69 during mid-day trading on Wednesday, hitting $409.71. 2,617,848 shares of the company traded hands, compared to its average volume of 2,735,858. The stock has a 50-day moving average price of $358.49 and a two-hundred day moving average price of $354.79. Amgen has a 12-month low of $269.77 and a 12-month high of $416.24. The stock has a market cap of $221.12 billion, a P/E ratio of 28.52, a P/E/G ratio of 3.83 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm earned $6.02 EPS. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen will post 22.31 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 70.15%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly earnings beat expectations: Amgen reported adjusted earnings of $6.29 per share, above the approximately $5.62 consensus estimate, while revenue rose 9.5% year over year to $10.05 billion versus expectations of $9.43 billion. Reuters earnings report
• Positive Sentiment: Higher 2026 guidance: Amgen now expects revenue of $38.2 billion to $39.4 billion, above the prior consensus of roughly $37.8 billion, and adjusted EPS of $22.30 to $23.50. The raised outlook signals confidence in continued product growth. Zacks earnings call analysis
• Positive Sentiment: Broad portfolio momentum: Twenty-two products posted double-digit sales growth. Repatha revenue increased 37% to $953 million and EVENITY sales rose 38% to $714 million, helping offset declines in mature products such as Prolia and XGEVA. Quiver Quantitative revenue report
• Positive Sentiment: Analyst target increases: BMO Capital Markets and Oppenheimer raised their price targets to $450 and maintained bullish ratings. Morgan Stanley, Wells Fargo, Canaccord and several other firms also lifted targets following the results, although most retained neutral or negative ratings.
• Neutral Sentiment: Pipeline investment remains important: Management plans to use the stronger financial performance to advance multiple late-stage programs, including obesity candidate MariTide. However, early development of another potential obesity treatment was halted, leaving investors focused on execution and future clinical data. Wall Street Journal outlook report
• Negative Sentiment: Ongoing risk factors: Reports of a patient-data breach and regulatory scrutiny related to Tavneos could create legal, reputational and operational costs. Recent insider activity also shows four sales and no purchases over the past six months, while several analysts’ targets remain below the current trading level.

Institutional Trading of Amgen

A number of large investors have recently added to or reduced their stakes in AMGN. Sfam LLC purchased a new stake in shares of Amgen during the 4th quarter worth approximately $38,000. Advocate Investing Services LLC bought a new position in shares of Amgen during the 4th quarter worth $39,000. Garton & Associates Financial Advisors LLC purchased a new stake in Amgen in the 4th quarter worth about $52,000. Binnacle Investments Inc boosted its position in Amgen by 26.1% during the third quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock worth $59,000 after purchasing an additional 43 shares during the period. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Amgen by 21.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 189 shares of the medical research company’s stock worth $62,000 after purchasing an additional 33 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.